+65 3158 9940
1300 798 820
+64 9801 0299
Singapore, 23 July 2020: Independent pharmaceutical company Specialised Therapeutics Asia (ST Asia) has appointed two senior executives to its Singapore team, as it drives commercialisation of new oncology products in the region. Dr Bhuvana Ramaswamy will commence as Senior Medical Advisor for South East Asia in October, bringing extensive oncology, scientific and pharmaceutical industry expertise to the
Singapore, 17 July 2020: A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now approved for use in Malaysia. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have had surgery, chemotherapy and prior trastuzumab-based therapy. It has been shown to significantly reduce
Singapore and Melbourne, Australia, 3 June 2020: A NOVEL marine-derived drug to treat Small Cell Lung Cancer (SCLC) has been granted a provisional designation by the Therapeutic Goods Administration (TGA), based on encouraging results from an international trial evaluating its safety and efficacy in several solid tumours, including SCLC. Data from a key Phase 2
Singapore, 23 April 2020: A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now commercially available to Singapore patients. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have had surgery, chemotherapy and prior trastuzumab-based therapy. It has been shown to significantly reduce
Singapore, 18 December, 2019: Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an exclusive license deal with US-based Onconova Therapeutics (NASDAQ: ONTX), securing commercialisation rights to a new therapy for the treatment of Myelodysplastic Syndrome (MDS). The drug, known as rigosertib, is currently in a Phase 3 clinical trial to assess the efficacy and
Singapore, 3 December, 2019: A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence has received approval in Singapore – at least six months ahead of its expected schedule. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have had surgery, chemotherapy and prior trastuzumab-based
Singapore and Melbourne, Australia, 14 October 2019: Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients in Australia, New Zealand and throughout SE Asia. Under the terms of the agreement, STA will provide the marine-derived compound YONDELIS (trabectedin) to patients
Melbourne, Australia and Atlanta, Georgia, 5 August 2019: Australian patients with diabetes-induced eye disease can now access a new treatment option that provides consistent and continuous treatment with long-lasting effect. The Therapeutic Goods Administration has now approved the drug ILUVIEN® (fluocinolone acetonide intravitreal implant), which delivers fluocinolone acetonide via a sustained release implant and provides therapeutic effect
Singapore, 17 May 2019: Independent pharmaceutical company Specialised Therapeutics Asia (STA) is launching an innovative tracking system that will enable real time monitoring of every unit of drug product provided through its supply chain – from packing to patient. The company, which markets specialist medicines to patients in Australia, New Zealand and across South East Asia,
19 March 2019: A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer has today been approved for use in Australian patients. The drug, NERLYNX (neratinib) is an oral medication taken for 12 months by women with early stage HER2-positive (HER2+) breast cancer. It is